Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

92.67EUR
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
€92.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
407,306
52-wk High
€100.35
52-wk Low
€70.68

Select another date:

Tue, Nov 29 2016

Photo

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT, Nov 29 German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

UPDATE 1-Merck KGaA expects profit gain from lower development costs

* Shares rise 3 pct in early Frankfurt trade (Adds details on reasons for higher guidance, fertility treatment)

Merck KGaA lifts profit guidance on lower development costs

FRANKFURT, Nov 15 German drugs and lab supplies maker Merck KGaA lifted its full-year profit forecast on lower drug development costs.

BRIEF-Merck KGaA says primary endpoint was not met in study population

* Merck KGaA - primary endpoint was not met in overall study population

BRIEF-Merck and Idemitsu sign collaboration agreement in the OLED material business

* Merck and Idemitsu sign collaboration agreement in the OLED material business

BRIEF-MERCK KGaA presents mid-stage data of atacicept at 2016 ACR/ARHP Annual Meeting

* Press release - merck kgaa, darmstadt, germany, presents phase ii data on the safety and efficacy of atacicept at the 2016 acr/arhp annual meeting Source text for Eikon: Further company coverage:

Juniper Pharma to restate results since 2013

Oct 24 Drug developer Juniper Pharmaceuticals Inc said it would have to restate its financial statements since 2013 due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA .

BRIEF-Juniper Pharmaceuticals- board determined financial statements for years ended 2013 through Dec 31, 2015 should no longer be relied upon

* Juniper Pharmaceuticals- board determined financial statements for years ended 2013 through Dec 31, 2015 should no longer be relied upon due to error identified

Select another date: